期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers 被引量:1
1
作者 Minoru Tada Yousuke Nakai +16 位作者 Takashi Sasaki Tsuyoshi Hamada rie nagano Dai Mohri Koji Miyabayashi Keisuke Yamamoto Hirofumi Kogure Kazumichi Kawakubo Yukiko Ito Natsuyo Yamamoto Naoki Sasahira Kenji Hirano Hideaki Ijichi Keishuke Tateishi Hiroyuki Isayama Masao Omata Kazuhiko Koike 《World Journal of Clinical Oncology》 CAS 2011年第3期158-163,共6页
Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade.New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs.Gemcitabine plus erlotinib was the only ... Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade.New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs.Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival,although the effect was minimal.Little or no improvement in survival with recent moleculartargeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer.Recently,the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time.For biliary tract cancer,gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy.Further improvement in survival is expected by the addition of cetuximab. 展开更多
关键词 CISPLATIN EPIDERMAL growth factor receptor GEMCITABINE K-RAS S-1
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部